• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单克隆抗体-长春花生物碱偶联物KS1/4-DAVLB(LY256787)在Fischer 344大鼠和恒河猴体内的处置情况。

Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.

作者信息

Spearman M E, Goodwin R M, Kau D

机构信息

Department of Drug Disposition, Eli Lilly and Company Corporate Center, Indianapolis, IN 46285.

出版信息

Drug Metab Dispos. 1987 Sep-Oct;15(5):640-7.

PMID:2891480
Abstract

The conjugate, KS1/4-DAVLB, of the murine monoclonal antibody KS1/4 with the vinca alkaloid 4-desacetylvinblastine (DAVLB) was administered intravenously to rats and monkeys. Terminal plasma half-life (t1/2) values were measured as radioequivalents and as functionally immunoreactive antibody conjugate after dosing with KS1/4-[3H]DAVLB. The t1/2 values, determined radiometrically, were 145 hr and 62 hr in male rats after 10 and 100 mg/kg doses and 92 hr and 90 hr in male and female monkeys after a 40 mg/kg dose. Comparable results were obtained when the functionally immunoreactive conjugate concentrations were determined by an enzyme-linked immunosorbent assay technique. The ratio of 35S:3H in the plasma after dosing rats with 100 mg/kg [35S]KS 1/4-[3H]DAVLB remained reasonably constant during 336 hr. Less than 1% of the total vinca alkaloid equivalents present in the plasma at any time could be extracted as free vinca species; the major vinca alkaloid metabolities present at early time points were hemisuccinate derivatives of DAVLB, whereas, at later times, DAVLB and its N-oxide were equally as concentrated. The major pathway of elimination was fecal with about one-half of the administered radioactivity cleared in 150-250 hr. After dosing with [35S]KS 1/4-[3H]DAVLB, the ratio of 35S:3H radioactivity in the bile was substantially less than that in the plasma. Evaluation of radioactivity eluted from the bile by size-exclusion HPLC showed that almost all of the tritium was associated with material of lower molecular weight than that of KS 1/4-DAVLB.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

将鼠单克隆抗体KS1/4与长春花生物碱4-去乙酰长春花碱(DAVLB)的偶联物KS1/4 - DAVLB静脉注射给大鼠和猴子。用KS1/4 - [³H]DAVLB给药后,以放射性等效物和功能性免疫反应性抗体偶联物的形式测量终末血浆半衰期(t1/2)值。通过放射性测量法确定,在雄性大鼠中,10和100mg/kg剂量后的t1/2值分别为145小时和62小时;在雄性和雌性猴子中,40mg/kg剂量后的t1/2值分别为92小时和90小时。当通过酶联免疫吸附测定技术测定功能性免疫反应性偶联物浓度时,得到了类似的结果。给大鼠注射100mg/kg [³⁵S]KS 1/4 - [³H]DAVLB后,血浆中³⁵S:³H的比值在336小时内保持相当恒定。在任何时候,血浆中存在的总长春花生物碱等效物中,不到1%可以作为游离长春花碱类物质被提取出来;早期时间点存在的主要长春花生物碱代谢物是DAVLB的半琥珀酸衍生物,而在后期,DAVLB及其N - 氧化物的浓度相当。主要的消除途径是粪便,给药后约一半的放射性在150 - 250小时内清除。用[³⁵S]KS 1/4 - [³H]DAVLB给药后,胆汁中³⁵S:³H放射性的比值明显低于血浆中的比值。通过尺寸排阻高效液相色谱法对从胆汁中洗脱的放射性进行评估表明,几乎所有的氚都与分子量低于KS1/4 - DAVLB的物质相关。(摘要截断于250字)

相似文献

1
Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.单克隆抗体-长春花生物碱偶联物KS1/4-DAVLB(LY256787)在Fischer 344大鼠和恒河猴体内的处置情况。
Drug Metab Dispos. 1987 Sep-Oct;15(5):640-7.
2
Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
J Pharmacol Exp Ther. 1987 May;241(2):695-703.
3
Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys.KS1/4单克隆抗体-去乙酰长春碱酰肼缀合物LY203725在大鼠和猴子体内的药代动力学及处置情况。
J Pharmacol Exp Ther. 1990 Mar;252(3):1117-24.
4
Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas.鼠单克隆抗体长春花共轭物(KS1/4 - DAVLB)在腺癌患者中的处置情况。
Clin Pharmacol Ther. 1990 Jan;47(1):36-41. doi: 10.1038/clpt.1990.5.
5
Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
Cancer Res. 1990 Jun 15;50(12):3540-4.
6
The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.在单剂量和多剂量临床研究中人类对KS1/4-去乙酰长春碱(LY256787)和KS1/4-去乙酰长春碱酰肼(LY203728)的免疫反应。
Cancer Res. 1991 May 1;51(9):2286-90.
7
Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.人白细胞弹性蛋白酶的口服活性抑制剂。I. L-683,845在大鼠和恒河猴体内的处置情况。
Drug Metab Dispos. 1996 Dec;24(12):1369-77.
8
The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory.制剂和水分对冻干单克隆抗体-长春花属植物缀合物稳定性的影响:WLF玻璃化转变理论的验证
Dev Biol Stand. 1992;74:323-39; discussion 340.
9
Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.用于卵巢癌治疗的化学免疫缀合物研发:长春花生物碱-单克隆抗体构建体的临床前研究
Bioconjug Chem. 1993 Mar-Apr;4(2):121-6. doi: 10.1021/bc00020a003.
10
Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.人白细胞弹性蛋白酶的口服活性抑制剂。II. L-694,458在大鼠和恒河猴体内的处置情况。
Drug Metab Dispos. 1997 Aug;25(8):932-9.

引用本文的文献

1
Prodrugs for improving tumor targetability and efficiency.前药提高肿瘤靶向性和疗效。
Adv Drug Deliv Rev. 2011 Jul 18;63(8):659-70. doi: 10.1016/j.addr.2011.02.002. Epub 2011 Feb 17.
2
Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate.由抗人结肠癌单克隆抗体与丝裂霉素C-葡聚糖缀合物组成的免疫缀合物的肿瘤定位及体内抗肿瘤活性
Jpn J Cancer Res. 1991 Feb;82(2):219-26. doi: 10.1111/j.1349-7006.1991.tb01832.x.
3
Preclinical and clinical pharmacology of vinca alkaloids.
长春花生物碱的临床前及临床药理学
Drugs. 1992;44 Suppl 4:1-16; discussion 66-9. doi: 10.2165/00003495-199200444-00002.